Kamada Ltd. Reports Financial Results for Q4 and Full Year 2024: A Detailed Analysis
On March 5, 2025, Kamada Ltd., a leading global biopharmaceutical company specializing in rare and serious conditions, with a significant focus on the specialty plasma-derived field, announced its financial results for the fourth quarter and the full year that ended on December 31, 2024. The company’s shares traded on the NASDAQ under the ticker KMDA and on the Tel Aviv Stock Exchange under KMDA.TA.
Key Financial Highlights:
The following table provides an overview of the financial highlights for Q4 and FY 2024:
| Q4 2024 | FY 2024 | |
|---|---|---|
| Total Revenue: | $125.7 million | $452.9 million |
| Cost of Sales: | $64.8 million | $219.8 million |
| Gross Profit: | $60.9 million | $233.1 million |
| Operating Income: | $(1.5) million | $25.5 million |
| Net Income: | ($(1.8) million) | $18.3 million |
Business Updates:
During the year, Kamada reported several significant business updates:
- Completed the acquisition of the plasma collection center in Rehovot, Israel, expanding its plasma collection capabilities and enhancing its in-house production of plasma-derived products.
- Achieved approval for its long-acting C1 esterase inhibitor, C1 Esterase Inhibitor (Human), for the treatment of hereditary angioedema in the European Union and the United States.
- Initiated a Phase 3 clinical trial for its extended half-life subcutaneous (SC) formulation of C1 Esterase Inhibitor (Human) in patients with hereditary angioedema.
- Announced a collaboration with the University of California, San Francisco (UCSF) to develop a novel plasma-derived therapeutic for neurodegenerative diseases.
Impact on Individuals:
For individuals with hereditary angioedema, Kamada’s financial results and business updates bring promising news. The company’s long-acting C1 esterase inhibitor, C1 Esterase Inhibitor (Human), is now approved in the EU and the US, and the ongoing Phase 3 clinical trial for the SC formulation could potentially lead to a more convenient and effective treatment option for patients.
Impact on the World:
The biopharmaceutical industry, and specifically the plasma-derived field, is poised for significant growth as companies like Kamada continue to invest in research, development, and production capabilities. The acquisition of the plasma collection center in Rehovot, Israel, is a testament to Kamada’s commitment to expanding its production capabilities, which could lead to increased availability and accessibility of plasma-derived therapies for patients worldwide. Moreover, the collaboration with UCSF on a novel plasma-derived therapeutic for neurodegenerative diseases could potentially lead to groundbreaking treatments for various diseases, including Alzheimer’s and Parkinson’s.
Conclusion:
Kamada Ltd.’s financial results for the fourth quarter and full year 2024 reflect the company’s continued progress in the rare and serious conditions market, particularly in the specialty plasma-derived field. The acquisition of the plasma collection center in Rehovot, Israel, and the approvals and clinical trial progress for C1 Esterase Inhibitor (Human) demonstrate Kamada’s commitment to expanding its capabilities and delivering innovative treatments for patients. The potential impact on individuals with hereditary angioedema is significant, while the collaboration with UCSF could lead to groundbreaking therapies for neurodegenerative diseases. Overall, Kamada’s achievements and future plans underscore the potential for continued growth and innovation in the plasma-derived field and the biopharmaceutical industry as a whole.
